Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1)
Public ClinicalTrials.gov record NCT02091375. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Double Blind, Placebo Controlled Two-part Study to Investigate the Dose-ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome
Study identification
- NCT ID
- NCT02091375
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Enrollment
- 120 participants
Conditions and interventions
Conditions
Interventions
- GWP42003-P 20 mg/kg/day Dose Drug
- Placebo control Drug
Drug
Eligibility (public fields only)
- Age range
- 2 Years to 18 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 29, 2015
- Primary completion
- Nov 25, 2015
- Completion
- Nov 25, 2015
- Last update posted
- Sep 27, 2022
2015
United States locations
- U.S. sites
- 13
- U.S. states
- 12
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Miami | Florida | 33155 | — |
| Not listed | Orlando | Florida | 32819 | — |
| Not listed | Atlanta | Georgia | 30328 | — |
| Not listed | Chicago | Illinois | 60611 | — |
| Not listed | Iowa City | Iowa | 52242 | — |
| Not listed | Boston | Massachusetts | 02114 | — |
| Not listed | Rochester | Minnesota | 55905 | — |
| Not listed | New York | New York | 10016 | — |
| Not listed | Winston-Salem | North Carolina | 27408 | — |
| Not listed | Columbus | Ohio | 43205 | — |
| Not listed | Philadelphia | Pennsylvania | 19104 | — |
| Not listed | Houston | Texas | 77030 | — |
| Not listed | Salt Lake City | Utah | 84113 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02091375, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 27, 2022 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02091375 live on ClinicalTrials.gov.